Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 39 - Medicinal preparations containing antigens or antibodies
Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
12/2005
12/15/2005US20050276807 Treatment of acne
12/15/2005US20050276806 Treatment of autism
12/15/2005US20050276805 Antibody molecules having a Fc region with complex N-glycoside-linked sugar chains bound it through an N-acetylglucosamine of the reducing terminal of the sugar chains, which do not contain chains with a fucose bound to the N-acetylglucosamines.
12/15/2005US20050276804 Method for preventing or treating cardiac hypertrophy
12/15/2005US20050276803 Method for augmenting B cell depletion
12/15/2005US20050276802 Comprising a variable heavy (VH) domain that has non-human hypervariable region residues incorporated into a human VH domain, said variable domain comprising a framework region (FR) substitution; anticarcinogenic agents, angiogenesis inhibitors; immunoaffinity chromatography, immunoassay; containers
12/15/2005US20050276801 Method of treatment using humanized anti-CD11a antibodies
12/15/2005US20050276799 Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
12/15/2005US20050276798 with a histidine buffer and maltose; anti-HIV; higher concentrations, are storage stable, compatible with lyophilization, and safe to administer by intravenous injection
12/15/2005US20050276797 Methods of priming the immunogenic activity of vaccines useful for eliciting a protective immune response
12/15/2005US20050276789 Immunostimulatory oligonucleotides and uses thereof
12/15/2005US20050276756 Compositions as adjuvants to improve immune responses to vaccines and methods of use
12/15/2005DE102004022927A1 1,4 O-verknüpfte Saccharose-Derivate zur Stabilisierung von Antikörpern oder Antikörper-Derivaten 1,4 O-linked saccharose derivative instruments for stabilizing antibodies or antibody derivatives
12/15/2005DE102004022926A1 Sprühgetrocknete Pulver enthaltend zumindest ein 1,4 O-verknüpftes Saccharose-Derivat und Verfahren zu deren Herstellung Spray-dried powder containing at least one 1,4 O-linked saccharose derivative, and processes for their preparation
12/15/2005DE10128980B4 Gen-modifizierte alloreaktive T-Zellen, Verfahren zu ihrer Herstellung und ihre Verwendung Gene-modified alloreactive T-cells, processes for their preparation and their use
12/15/2005CA2776051A1 Binding molecules capable of neutralizing rabies virus and uses thereof
12/15/2005CA2775807A1 Binding molecules capable of neutralizing rabies virus and uses thereof
12/15/2005CA2742088A1 Antibodies that bind psca proteins for diagnosis of cancer
12/15/2005CA2608003A1 Medical uses of carrier conjugates of non-human tnf-peptides
12/15/2005CA2572451A1 Annexin a1 based vascular targets for detecting, imaging and treating neoplasia or neovasculature
12/15/2005CA2572348A1 Tissue-specific imaging and therapeutic agents targeting proteins expressed on lung endothelial cell surface
12/15/2005CA2570156A1 Needle-free administration of felv vaccines
12/15/2005CA2569276A1 Preservation by vaporization
12/15/2005CA2568838A1 Nucleic acids, polypeptides, methods of expression, and immunogenic compositions associated with sars corona virus spike protein
12/15/2005CA2568642A1 Cynomolgus prostate specific antigen
12/15/2005CA2568364A1 Methods for preparing immunogenic conjugates
12/15/2005CA2568345A1 Inhibitors of regiii proteins as asthma therapeutics
12/15/2005CA2568344A1 Novel artificial antigen presenting cells and uses therefor
12/15/2005CA2568162A1 Binding molecules capable of neutralizing rabies virus and uses thereof
12/15/2005CA2567526A1 Cancer treatment method by inhibiting mage gene expression or function
12/15/2005CA2567520A1 Maytansinoid-antibody conjugates
12/15/2005CA2567491A1 Immune response assessment method
12/15/2005CA2567449A1 Antibodies and related molecules that bind to psca proteins
12/15/2005CA2567030A1 Stable peptide mimetic of hiv gp41 fusion intermediate
12/15/2005CA2566979A1 Use of a cd20 antibody in treatment of multiple sclerosis
12/15/2005CA2566975A1 Method to reduce hepatotoxicity of fas-mediated apoptosis-inducing agents
12/15/2005CA2566971A1 Treatment with irinotecan (cpt-11) and an egfr-inhibitor
12/15/2005CA2566506A1 Peptides for inducing a ctl and/or htl response to hepatitis c virus
12/15/2005CA2565827A1 Bispecific binding agents for modulating biological activity
12/15/2005CA2565500A1 Vaccine compositions comprising virosomes and a saponin adjuvant
12/15/2005CA2564529A1 Preventing autoimmune disease
12/15/2005CA2564098A1 Solution phase biopanning method using engineered decoy proteins
12/15/2005CA2564092A1 Methods and compositions for the treatment of polycystic diseases
12/15/2005CA2563445A1 Compositions and methods for modulating vascular development
12/15/2005CA2562771A1 Anti-il-9 antibody formulations and uses thereof
12/15/2005CA2561861A1 Antibodies to angiogenesis inhibiting domains of cd148
12/15/2005CA2561823A1 Antibodies of angiogenesis inhibiting domains of cd148
12/14/2005EP1605061A1 Neisseria genomic sequences and methods of their use
12/14/2005EP1605052A2 A method for producing influenza hemagglutinin multivalent vaccines
12/14/2005EP1605049A2 Fibrinolytically active polypeptide
12/14/2005EP1605047A1 Chimeric and/or growth-restricted flaviviruses
12/14/2005EP1604997A1 Human polyclonal antibodies from transgenic nonhuman animals
12/14/2005EP1604996A2 An allergenic protein complex of natural rubber latex
12/14/2005EP1604688A1 Stabilised mRNA with increased G/C-content and optimised codon usage for gene therapy
12/14/2005EP1604685A2 An attenuated japanese encephalitis virus
12/14/2005EP1604684A1 Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens
12/14/2005EP1604683A2 Subcutaneously-administered ganglioside-based vaccine compositions
12/14/2005EP1604184A2 Standardized evaluation of therapeutic efficacy based on cellular biomarkers
12/14/2005EP1604009A2 Method for identifying risk of melanoma and treatments thereof
12/14/2005EP1603951A1 Soluble hybrid prion proteins and their use in the diagnosis, prevention and treatment of transmissible spongiform encephalopathies
12/14/2005EP1603950A2 Mutant cholera holotoxin as an adjuvant and an antigen carrier protein
12/14/2005EP1603941A1 Inhibitors of extracellular hsp90
12/14/2005EP1603940A2 Process for increasing rsv surface glycoprotein yields using a mutant strain of rsv
12/14/2005EP1603938A2 Inclusion bodies as antigens for the oral vaccination of animals against csfv
12/14/2005EP1603936A2 Use of lectins to promote oligomerization of glycoproteins and antigenic molecules
12/14/2005EP1603593A2 Pharmaceutical composition
12/14/2005EP1603591A2 Allergen peptide fragments and use thereof
12/14/2005EP1603590A2 Influenza virus vaccine
12/14/2005EP1603511A2 Treatment of igai deposition diseases
12/14/2005EP1603391A1 Methods for using compositions comprising heat shock proteins or alpha-2-macroglobulin in the treatment of cancer and infectious disease
12/14/2005EP1280904B1 Pain signaling molecules
12/14/2005EP1217989B1 Vaccines for oral use which contain liposome-entrapped dna
12/14/2005EP1178821B1 Use of anti-hbp antibodies in the inhibition of bradykinin release
12/14/2005EP1165125B1 Antigen-specific induction of peripheral immune tolerance
12/14/2005EP1114160B1 Moraxella catarrhalis basb034 polypeptides and uses thereof
12/14/2005EP1086229B1 Moraxella catarrhalis polynucleotides and polypeptides
12/14/2005EP1080198B1 Neisseria meningitidis antigenic polypeptides, corresponding polynucleotides and protective antibodies
12/14/2005EP1007666B1 Neurturin receptor
12/14/2005EP0927045B1 Tumor homing molecules, conjugates derived therefrom, and methods of using same
12/14/2005EP0858504B1 Diagnostics and treatments of periodontal disease
12/14/2005EP0832255B1 Recombinant bacterial system with environmentally limited viability
12/14/2005CN1708587A Recombinant MVA strains as potential vaccines against p. falciparum malaria
12/14/2005CN1708506A Polysaccharide vaccine for staphylococcal infections
12/14/2005CN1708317A Combination therapy with class III anti-CEA monoclonal antibodies and therapeutic agents
12/14/2005CN1706955A Construction and application of oncolytic adenovirus recombinant of tumor cell specifically expressing immunoregulation factor GM-CSF
12/14/2005CN1706497A Inactivate pig parvovirus disease oil emulsion vaccine
12/14/2005CN1706496A Genetically engineered vaccine resisting vibriosis of marine cultured animal and its prepn and use
12/14/2005CN1706495A New type of cell vaccine with heteroimmune cell as cell vector and its prepn process
12/14/2005CN1706494A Method of preparing dust mite allergen vaccine with nano particle carrier
12/14/2005CN1231598C Process for recombining aviadenovirus
12/14/2005CN1231589C Eukaryotic gene expression cassette and uses thereof
12/14/2005CN1231586C Polymorphic saccharomyces hansenii expression recombination cholere toxin B subunit gene and its application
12/14/2005CN1231585C Method for preparing recombinant duck interleukin-2 protein and its application
12/14/2005CN1231578C Attenuated virus of ox's viral diarrhea
12/14/2005CN1231573C Lawsonia intracellularis cultivation, anti-lawsonia intracellularis vaccines and diagnostic agents
12/14/2005CN1231264C Liquid formulation comprising cetuximab and a fatty acid ester of polyoxyethylene sorbitan
12/14/2005CN1231263C Foot-and-mouth disease virus antigen preservation technology
12/14/2005CN1231262C Mimetic peptides for epitope of apolipoprotein B-100, concatemer and modified peptides, and vaccine composition comprising the same
12/13/2005US6974867 Compositions and methods for treating neoplastic disease using chemotherapy and radiation sensitizers
12/13/2005US6974866 Retrovirus from the HIV type O and its use (MVP-2901/94)
1 ... 1005 1006 1007 1008 1009 1010 1011 1012 1013 1014 1015 1016 1017 1018 1019 1020 1021 1022 1023 1024 1025 ... 1823